Ipamorelin - Complete Research Paper

1. Summary

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that acts as a selective agonist of the ghrelin/GHS receptor (GHSR-1a). Originally developed by Novo Nordisk in Denmark, ipamorelin is notable for being the first GHS with selectivity for growth hormone release comparable to GHRH—meaning it stimulates GH release without significantly affecting cortisol, ACTH, or prolactin levels, unlike older GHS compounds such as GHRP-2 and GHRP-6.

IMPORTANT REGULATORY STATUS: Ipamorelin is NOT FDA-approved for any therapeutic indication in humans. In 2023, the FDA added ipamorelin to Category 2 of its compounding list, effectively banning its use in compounding pharmacies. Current availability is severely restricted, though the regulatory landscape continues to evolve.

Developer: Novo Nordisk (original); Helsinn Therapeutics (clinical trials) Chemical Class: Growth Hormone Secretagogue (GHS) / Growth Hormone Releasing Peptide (GHRP) Structure: Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) Molecular Formula: C₃₈H₄₉N₉O₅ Molecular Weight: ~711.85 Da

Key Clinical Features:

• Drug class: Growth hormone secretagogue (GHRP analog)
• Peptide length: 5 amino acids
• Administration: Subcutaneous or intravenous injection
• Half-life: ~2 hours (plasma)
• GH peak: ~0.67 hours post-injection
• Unique feature: First selective GHS—does not increase cortisol/ACTH

Primary Advantage: Ipamorelin's selectivity distinguishes it from other GHS compounds. While GHRP-6 and GHRP-2 stimulate GH release but also increase cortisol and ACTH, ipamorelin produces GH responses without affecting these stress hormones—even at doses 200-fold higher than the ED₅₀ for GH release. This selectivity profile is similar to that of native GHRH itself.

2. Mechanism of Action

Ipamorelin functions as a selective ghrelin receptor agonist.

Primary Mechanism:

1. GHSR-1a Binding: Ipamorelin binds to growth hormone secretagogue receptor 1a (GHSR-1a), the same receptor targeted by ghrelin
2. Pituitary Stimulation: Receptor activation stimulates somatotroph cells in the anterior pituitary
3. GH Release: Endogenous growth hormone is released in pulsatile bursts
4. IGF-I Elevation: Hepatic IGF-I production increases downstream

Receptor Pharmacology:

GHSR-1a (Ghrelin Receptor) Distribution:

Selectivity Profile (Key Differentiator):

This selectivity means ipamorelin stimulates GH without activating the hypothalamic-pituitary-adrenal (HPA) axis, avoiding stress hormone elevations.

Additional Pharmacological Effects:

• No significant effect on FSH, LH, prolactin, or TSH
• Does not significantly increase ghrelin-like appetite stimulation (unlike GHRP-6)
• May have prokinetic effects in gastrointestinal tract (basis for POI research)

Goal Archetype Integration

Ipamorelin serves multiple health optimization archetypes through its selective GH-releasing mechanism:

Primary Goal Alignment

Recovery & Healing

• GH elevation accelerates tissue repair and cellular regeneration
• Enhanced collagen synthesis supports connective tissue recovery
• Improved sleep quality amplifies natural recovery processes
• Reduced inflammation markers support post-exercise adaptation
• Primary Use Case: Athletes, post-surgical recovery, injury rehabilitation

Body Composition

• GH-mediated lipolysis promotes fat oxidation (particularly visceral fat)
• IGF-1 signaling supports lean muscle protein synthesis
• Enhanced nutrient partitioning favors muscle over adipose tissue
• Synergistic effects with resistance training and protein intake
• Primary Use Case: Body recomposition, fat loss while preserving muscle mass

Anti-Aging & Longevity

• Restores youthful GH pulsatility patterns that decline with age
• Supports skin elasticity through collagen and elastin production
• Maintains bone mineral density through GH/IGF-1 axis optimization
• Enhances cognitive function and neuroprotection (GH receptors in brain)
• Improves cardiovascular markers (GH supports endothelial function)
• Primary Use Case: Age-related GH decline, wellness optimization, vitality enhancement

When This Compound Makes Sense

• Adults experiencing age-related GH decline with symptoms (fatigue, reduced recovery, body composition changes)
• Those seeking enhanced recovery from training or injury without exogenous GH
• Individuals wanting to optimize sleep quality and natural GH pulsatility
• Non-competitive athletes seeking body composition improvements

When to Choose Something Else

• Active cancer or history of cancer (GH/IGF-1 may promote cell proliferation)
• Competitive athletes under WADA testing (ipamorelin is prohibited)
• Those seeking rapid, dramatic transformations (effects are subtle and gradual)
• Budget-constrained individuals (FDA-approved alternatives may be more cost-effective long-term)

3. FDA-Approved Indications

IPAMORELIN IS NOT FDA-APPROVED FOR ANY INDICATION

Ipamorelin has never received FDA approval for therapeutic use in humans.

Clinical Development History:

The POI Clinical Trial: Helsinn Therapeutics conducted a phase II, multicenter, double-blind, placebo-controlled trial (NCT00672074) evaluating ipamorelin for postoperative ileus management:

• 114 patients undergoing bowel resection
• Ipamorelin 0.03 mg/kg IV twice daily vs. placebo
• Treatment from POD 1 to POD 7 or discharge
• Result: Well tolerated, but no significant efficacy vs. placebo
• Trial discontinued

Off-Label/Compounding Uses (Historical): Prior to FDA Category 2 classification, ipamorelin was prescribed off-label through compounding pharmacies for:

• Adult growth hormone optimization
• Body composition enhancement
• Anti-aging/wellness applications
• Sleep quality improvement
• Athletic recovery

IMPORTANT: These uses have never been FDA-evaluated or approved.

4. Dosing and Administration

Note: No FDA-approved dosing exists. The following represents historical compounding pharmacy protocols and research applications.

Historical Compounding Pharmacy Dosing:

Split Dosing Protocol:

• Morning (fasted or post-workout): 100-150 µg
• Bedtime: 100-150 µg
• Rationale: Mimics natural GH pulsatility

Clinical Trial Dosing (POI Study):

• 0.03 mg/kg (30 µg/kg) IV twice daily
• Up to 7 days of treatment

Administration Notes:

• Subcutaneous injection preferred for outpatient use
• Common injection sites: Abdomen, thigh
• Administer 2+ hours before bedtime
• Inject at same time daily for consistency
• Reconstitute lyophilized powder with bacteriostatic water
• Use sterile technique

Pharmacokinetic Considerations:

• Peak GH response at ~40 minutes (0.67 hours)
• Bedtime administration aligns with natural nocturnal GH surge
• Fasting may enhance response

5. Pharmacokinetics

Absorption:

• Routes: Subcutaneous, intravenous
• SC Bioavailability: Not well characterized; assumed high based on peptide properties
• Time to GH peak: ~0.67 hours (40 minutes) post-injection

Distribution:

• Distributes to target tissues including pituitary, hypothalamus
• Volume of distribution not published
• GHSR-1a receptor distribution determines tissue effects

Metabolism:

• Rapid enzymatic degradation by plasma peptidases
• Classical protein catabolism
• No CYP450 involvement

Elimination:

• Half-life (plasma): ~2 hours
• Short half-life necessitates daily dosing
• Complete elimination within 12-24 hours

Pharmacodynamic Parameters:

Comparison with Other Secretagogues:

6. Side Effects and Adverse Reactions

Common/Mild Side Effects:

Injection Site Reactions:

• Mild pain
• Redness
• Swelling
• Itching

Systemic Effects:

Notable Absence of Side Effects (vs. other GHS):

• Does NOT significantly increase cortisol (unlike GHRP-2, GHRP-6)
• Does NOT cause significant appetite increase ("hungry" feeling)
• Does NOT cause "jittery" sensation

Potential Effects at High Doses:

• Carpal tunnel syndrome symptoms
• Joint tightness/stiffness
• Peripheral edema

Serious Adverse Events: The FDA cited a study with serious adverse events (including death) when ipamorelin was administered IV in experimental settings. These events occurred with IV infusion protocols far outside typical subcutaneous anti-aging dosing.

Long-term Safety:

• Limited long-term human data available
• Most evidence from short-term studies
• Unknown effects of chronic use

7. Drug Interactions

Testing Considerations:

• Stop exogenous GH therapy 1 week before testing
• Fasting state recommended for diagnostic protocols
• Avoid exercise before testing (elevates GH)

Synergistic Combinations (Historical): Ipamorelin was often combined with CJC-1295 (GHRH analog) in compounding:

• CJC-1295 provides sustained GHRH-receptor stimulation
• Ipamorelin provides pulsatile GHSR-1a activation
• Combination may enhance GH release amplitude

8. Contraindications

Absolute Contraindications:

Relative Contraindications/Precautions:

Sports/Athletic Considerations:

• Ipamorelin is PROHIBITED by WADA at all times
• Banned by most professional sports organizations
• Ghrelin mimetics are classified as performance-enhancing

9. Special Populations

Pediatric Patients:

• No approved pediatric uses
• Safety and efficacy not established
• Not indicated for pediatric growth hormone deficiency

Geriatric Patients:

• Historical target demographic for "anti-aging" applications
• Age-related GH decline is physiological
• Major medical organizations do not endorse GHS for anti-aging
• May be more sensitive to adverse effects

Pregnancy (Category Not Established):

• Safety not established
• Should be avoided during pregnancy
• Discontinue if pregnancy occurs

Lactation:

• Unknown if excreted in breast milk
• Should be avoided during breastfeeding

Renal Impairment:

• No specific dosing guidelines
• May have altered clearance
• Use with caution

Hepatic Impairment:

• Liver produces IGF-I
• May have altered response
• No specific dosing guidelines

10. Monitoring Parameters

Baseline Evaluation:

• IGF-I level
• Growth hormone (GH) - provocative testing if indicated
• Thyroid function (free T4, TSH)
• Fasting glucose and HbA1c
• Lipid panel
• Complete metabolic panel

Ongoing Monitoring:

Symptoms to Monitor:

• Joint pain or stiffness
• Carpal tunnel symptoms (tingling, numbness)
• Edema
• Headache
• Sleep quality changes

11. Cost and Availability

CRITICAL REGULATORY UPDATE: In 2023, the FDA placed ipamorelin in Category 2 of its compounding list, effectively banning its compounding by 503A and 503B pharmacies. This significantly restricts legitimate access in the United States.

Historical Pricing (Pre-2023, Compounding):

Current Availability Status:

Comparison to Alternatives:

Future Outlook: The FDA regulatory landscape for peptides continues to evolve. Changes in FDA advisory panel composition and regulatory approach may affect future availability.

12. Clinical Evidence Summary

Phase I Clinical Data:

• Ipamorelin demonstrated safety in phase I trials
• Dose-dependent GH release confirmed
• Short-term tolerability established
• Provided foundation for phase II development

Phase II Postoperative Ileus Trial (NCT00672074):

Preclinical Evidence: Rodent studies demonstrated:

• Accelerated gastric emptying
• Improved GI motility
• Activation via ghrelin receptor-cholinergic mechanism
• Dose-dependent effects on bowel function

Limitations of Evidence Base:

• No completed phase III trials
• No FDA approval for any indication
• Most "anti-aging" claims based on GH mechanism, not direct ipamorelin studies
• Limited long-term safety data
• Off-label uses lack robust clinical trial support

13. Comparison with Alternatives

Advantages of Ipamorelin:

1. Selectivity: Does not elevate cortisol/ACTH
2. Tolerability: Minimal appetite stimulation
3. Safety profile: No significant HPA axis effects
4. Pulsatile release: More physiological than constant rhGH

Disadvantages:

1. Regulatory status: Banned for compounding (Category 2)
2. Efficacy evidence: Phase II trial failed for POI
3. Access: Severely limited in legitimate channels
4. Long-term data: Insufficient safety data

14. Storage and Handling

Lyophilized (Before Reconstitution):

• Store at room temperature or refrigerated
• Protect from light
• Keep in original packaging
• Stable for months when properly stored

After Reconstitution:

Reconstitution Instructions:

1. Use bacteriostatic water (preferred) or sterile water
2. Inject diluent slowly down vial wall
3. Swirl gently—do NOT shake
4. Allow to dissolve completely
5. Solution should be clear; discard if cloudy

Injection Supplies:

• Insulin syringes (0.3 mL or 0.5 mL)
• Alcohol swabs
• Sharps container
• Bacteriostatic water for injection

15. References

1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. Available at: https://pubmed.ncbi.nlm.nih.gov/9849822/

2. ClinicalTrials.gov. Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus. NCT00672074. Available at: https://clinicaltrials.gov/ct2/show/results/NCT00672074

3. Greenwood-Van Meerveld B, et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116. Available at: https://pubmed.ncbi.nlm.nih.gov/19289567/

4. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Available at: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

5. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37. Available at: https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9

6. BodySpec. CJC-1295 Ipamorelin: Research, Safety, and Results. Available at: https://www.bodyspec.com/blog/post/cjc1295_ipamorelin_research_safety_and_results

7. Swolverine. Ipamorelin Dosage Guide: Optimal Protocols for Recovery and Muscle Growth. Available at: https://swolverine.com/blogs/blog/ipamorelin-dosage-guide-optimal-protocols-for-recovery-and-muscle-growth

8. Wikipedia. Ipamorelin. Available at: https://en.wikipedia.org/wiki/Ipamorelin

9. Peptides.org. Ipamorelin Cost: What to Know. Available at: https://www.peptides.org/ipamorelin-cost/

10. Drugs.com. Ipamorelin Information. Available at: https://www.drugs.com/

Document compiled from peer-reviewed literature, clinical trial databases, and regulatory documents. Last updated: December 2024.

Regulatory Disclaimer: Ipamorelin is not FDA-approved for any therapeutic indication. As of 2023, it is classified in FDA Category 2, effectively banning its use in compounding pharmacies. This document is for informational purposes only and does not constitute medical advice or endorsement of off-label use.

Status: PAPER 75 OF 76 COMPLETE

Next Paper: #76 - Gonadorelin